Search by Drug Name or NDC
NDC 70710-1052-03 ATAZANAVIR 300 mg/1 Details
ATAZANAVIR 300 mg/1
ATAZANAVIR is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Zydus Pharmaceuticals USA Inc.. The primary component is ATAZANAVIR SULFATE.
MedlinePlus Drug Summary
Atazanavir is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children who are at least 3 months of age and weigh at least 22 lb (10 kg). Atazanavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although atazanavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Atazanavir must be given with other medications that treat HIV infection to completely treat the infection. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 70710-1052-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Atazanavir
Product Information
| NDC | 70710-1052 |
|---|---|
| Product ID | 70710-1052_071de592-e6a5-46c9-a3c8-a582411c6fe7 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | ATAZANAVIR |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ATAZANAVIR |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 300 |
| Active Ingredient Units | mg/1 |
| Substance Name | ATAZANAVIR SULFATE |
| Labeler Name | Zydus Pharmaceuticals USA Inc. |
| Pharmaceutical Class | Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210575 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 70710-1052-03 (70710105203)
| NDC Package Code | 70710-1052-3 |
|---|---|
| Billing NDC | 70710105203 |
| Package | 30 CAPSULE in 1 BOTTLE (70710-1052-3) |
| Marketing Start Date | 2021-05-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |